HIV/AIDS Clinical Trials in Los Angeles

Showing 361-380 of 648 trials

Immunologic Memory (Supp. of ATN 024)

NCT00142753

This is an exploratory, laboratory-based evaluation of cellular immune response to immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents. This is a substudy of ATN 024 and ATN 025. This substudy will compare cellular immune response in responders and nonresponders to immunization and also evaluate the relationship of these factors to the persistence of known correlates of serologic protection for the hepatitis B virus.

HIV Infections

University of North Carolina, Chapel Hill95 participantsStarted Aug 2005

Los Angeles, California, United States • San Franciso, California, United States • Washington D.C., District of Columbia, United States +1 more locations

COMPLETED< 1 mile

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders

NCT02438592

This is an observational study involving retrospective and prospective medical record review covering a total maximum of 104 weeks (24 months) per subject. An Audio Computer- Assisted Self-Interview (ACASI) at study entry will assess demographic and psychosocial variables of study subjects. Data will also be collected to assess clinic level variables. Definitions of engagement, prescription of antiretroviral therapy (ART), and viral suppression in the Continuum of Care (CoC) will utilize common definitions including those by U.S. Department of Health and Human Services (DHHS) and Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB). Data will be collected in a large, simple trial design manner to provide all elements for both the primary and secondary outcomes.

HIV

University of North Carolina, Chapel Hill924 participantsStarted Mar 2015

Aurora, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +11 more locations

Immunologic Memory (Supp. of ATN 024)

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders

HIV/AIDS Trials in Other Cities

Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth

C2P Mobilization Intervention (Pilot)

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

CDC-ATN Linkage Evaluation

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

An HIV Intervention for Black Men at Risk - The Enhanced Sexual Health Intervention for Men (ES-HIM)

A Study of HIV in Newly Infected Individuals

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

Expanded Access Program for Maraviroc At Multiple Centers

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Other Conditions in Los Angeles